Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukemia in people at high risk ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic stem ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

SON-1010, an engineered interleukin-12 cytokine, aims to activate the immune system to target tumor cells in sarcoma patients. The SB101 trial's Safety Review Committee found no unexpected toxicities ...

Milano presented findings from a Phase 2 trial of 14 patients with acute AML who went through CBT using a cryopreserved non-HLA-matched expanded progenitor cell product to enhance the graft versus ...